ApoB, non-HDL-C, and LDL-C Are More Prominent in Retinal Artery Occlusion Compared to Retinal Vein Occlusion

被引：3

作者：

Chen, Ting ^{[1
]}

Li, Ying ^{[1
]}

Wang, Yuedan ^{[1
]}

Li, Xuejie ^{[1
]}

Wan, Yuwei ^{[1
]}

Xiao, Xuan ^{[1
,2
]}

机构：

[1] Renmin Hosp Wuhan Univ, Wuhan, Hubei, Peoples R China

[2] Renmin Hosp Wuhan Univ, Dept Ophthalmol, 238 Jie Fang St, Wuhan 430060, Hubei, Peoples R China

来源：

OCULAR IMMUNOLOGY AND INFLAMMATION | 2024年 / 32卷 / 05期

关键词：

Atherosclerosis; biomarkers; lipid profile; retinal artery occlusion; retinal vein occlusion; DENSITY-LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN-B; RISK-FACTORS; ATHEROSCLEROSIS; INFLAMMATION; ASSOCIATION;

D O I：

10.1080/09273948.2023.2173245

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

PurposeTo evaluate and compare the blood lipid profile in retinal artery occlusion (RAO) and retinal vein occlusion (RVO).MethodsWe included 82 RAO patients and 95 RVO patients in this retrospective case-control study. Controls were matched to RAO or RVO patients at a 1:1 ratio, respectively. Associated lipid variates were analyzed in multivariable logistic regression models.ResultsLDL-C (OR = 1.69), non-HDL-C (OR = 1.87), and ApoB (OR = 11.72) individually significantly increased the risk of RAO. ApoA1 was associated with RVO (OR = 0.02), and with 75.8% sensitivity and 67.4% specificity. TG (OR = 1.61), LDL-C (OR = 1.69), non-HDL-C (OR = 1.91), and ApoB (OR = 12.12) each significantly increased the risk of RAO when compared with RVO.ConclusionsApoB, non-HDL-C, and LDL-C may be potential biomarkers in RAO patients. Low ApoA1 is an independent risk factor for the development of RVO.

引用

页码：534 / 540

页数：7

共 50 条

[1] The clinical utility of apoB versus LDL-C/non-HDL-C
Kohli-Lynch, Ciaran N.
Thanassoulis, George
Moran, Andrew E.
Sniderman, Allan D.
CLINICA CHIMICA ACTA, 2020, 508 : 103 - 108
[2] ApoB vs non-HDL-C vs LDL-C as Markers of Cardiovascular Disease
Sniderman, Allan D.
CLINICAL CHEMISTRY, 2021, 67 (11) : 1440 - 1442
[3] ApoB triumphs once more over LDL-C and non-HDL-C in risk prediction: ready for guidelines?
Mortensen, Martin Bodtker
EUROPEAN HEART JOURNAL, 2024,
[4] NON-HDL-C AND APOB GOALS EQUIVALENT TO LDL-C TARGETS IN MIXED DYSLIPIDEMIC PATIENTS
Garcia Castanon, S.
Calmarza Calmarza, P.
Cenarro Lagunas, A.
Ferrer Gimenez, M.
Villarroel Salcedo, M. T.
Civeira, F.
Puzo Foncillas, J.
ATHEROSCLEROSIS, 2014, 235 (02) : E200 - E201
[5] High levels of LDL-C, apoB, and non-HDL-C associated with coronary microvascular dysfunction
Yagyu, S.
Furuya, S.
Kikushima, K.
Tani, S.
Takahashi, H.
Iida, K.
Washio, T.
Niizuma, S.
Kawauchi, K.
Kobori, M.
Ashida, T.
Matsumoto, N.
Hirayama, A.
EUROPEAN HEART JOURNAL, 2017, 38 : 389 - 389
[6] Non-HDL-C is a Better Predictor for the Severity of Coronary Atherosclerosis Compared with LDL-C
Zhang, Yan
Wu, Na-Qiong
Li, Sha
Zhu, Cheng-Gang
Guo, Yuan-Lin
Qing, Ping
Gao, Ying
Li, Xiao-Lin
Liu, Geng
Dong, Qian
Li, Jian-Jun
HEART LUNG AND CIRCULATION, 2016, 25 (10): : 975 - 981
[7] Trends in LDL-C and Non-HDL-C Levels with Age
Zhang, Peng
Su, Qian
Ye, Xiaomiao
Guan, Ping
Chen, Chengjun
Hang, Yanwen
Dong, Jian
Xu, Zhongjie
Hu, Wei
AGING AND DISEASE, 2020, 11 (05): : 1046 - 1057
[8] The SANDS Trial: Does Aggressive Lowering of LDL-C and Non-HDL-C in Diabetes Decrease the Plasma ApoB and LDL-C Particle Number?
Howard, Barbara V.
Devereux, Richard B.
Fleg, Jerome L.
Howard, Wm. James
Mete, Mihriye
Otvos, James D.
Ratner, Robert E.
Roman, Mary J.
Russell, Marie
Umans, Jason G.
Weissman, Neil J.
CIRCULATION, 2008, 118 (18) : S1136 - S1136
[9] RELATIONSHIPS BETWEEN LDL-C, ApoB AND NON-HDL-C WITH hsCRP IN HYPERCHOLESTEROLEMIC PATIENTS AT RISK FOR CARDIOVASCULAR DISEASE
O'Keefe, J.
Abuannadi, M.
Lin, J.
Shah, A.
Neff, D.
Tomassini, J. E.
Tershakovec, A.
ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 112 - 112
[10] LDL-C、non-HDL-C和ApoB100的临床应用价值评价
彭及雅
李欣颖
张大庆
临床检验杂志, 2021, 39 (07) : 521 - 524

← 1 2 3 4 5 →